BR0308904A - Método de tratamento de gastroparesia, e, uso de um composto de glp-1 - Google Patents

Método de tratamento de gastroparesia, e, uso de um composto de glp-1

Info

Publication number
BR0308904A
BR0308904A BR0308904-5A BR0308904A BR0308904A BR 0308904 A BR0308904 A BR 0308904A BR 0308904 A BR0308904 A BR 0308904A BR 0308904 A BR0308904 A BR 0308904A
Authority
BR
Brazil
Prior art keywords
glp
gastroparesis
treatment
compound
compounds
Prior art date
Application number
BR0308904-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Joseph Anthony Jakubowski
Thurman Dwight Mckinney
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0308904A publication Critical patent/BR0308904A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR0308904-5A 2002-04-10 2003-03-27 Método de tratamento de gastroparesia, e, uso de um composto de glp-1 BR0308904A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37165002P 2002-04-10 2002-04-10
PCT/US2003/008457 WO2003087139A2 (en) 2002-04-10 2003-03-27 Treatment of gastroparesis

Publications (1)

Publication Number Publication Date
BR0308904A true BR0308904A (pt) 2005-05-03

Family

ID=29250714

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308904-5A BR0308904A (pt) 2002-04-10 2003-03-27 Método de tratamento de gastroparesia, e, uso de um composto de glp-1

Country Status (18)

Country Link
US (1) US20050164925A1 (enExample)
EP (1) EP1496924A4 (enExample)
JP (1) JP2005530732A (enExample)
KR (1) KR20040098063A (enExample)
CN (1) CN1735423A (enExample)
AU (1) AU2003220403A1 (enExample)
BR (1) BR0308904A (enExample)
CA (1) CA2480858A1 (enExample)
EA (1) EA200401345A1 (enExample)
EC (1) ECSP045345A (enExample)
HR (1) HRP20040939A2 (enExample)
IL (1) IL164266A0 (enExample)
MX (1) MXPA04009929A (enExample)
NO (1) NO20044815L (enExample)
NZ (1) NZ535684A (enExample)
PL (1) PL373658A1 (enExample)
WO (1) WO2003087139A2 (enExample)
ZA (1) ZA200408111B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US8792985B2 (en) 2003-07-21 2014-07-29 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
EP1667724A2 (en) 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
WO2005027978A2 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
WO2006018851A2 (en) 2004-08-18 2006-02-23 Metacure Ltd. Monitoring, analysis, and regulation of eating habits
WO2006087712A2 (en) 2005-02-17 2006-08-24 Metacure N.V. Charger with data transfer capabilities
US9821158B2 (en) 2005-02-17 2017-11-21 Metacure Limited Non-immediate effects of therapy
RU2007134155A (ru) 2005-03-18 2009-04-27 Ново Нордиск А/С (DK) Glp-1 соединения с увеличенным временем полужизни
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2006129321A2 (en) 2005-06-02 2006-12-07 Metacure N.V. Gi lead implantation
ATE533403T1 (de) * 2005-03-24 2011-12-15 Metacure Ltd Drahtlose leitungen für magen-darm-trakt- anwendungen
US8463404B2 (en) 2005-03-24 2013-06-11 Metacure Limited Electrode assemblies, tools, and methods for gastric wall implantation
US8442841B2 (en) * 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
AU2012203915B9 (en) * 2006-04-20 2014-10-09 Amgen Inc. GLP-1 compounds
MX2008013304A (es) * 2006-04-20 2008-10-27 Amgen Inc Compuestos de peptido 1 tipo glucagon.
WO2008139463A2 (en) * 2007-05-09 2008-11-20 Metacure Ltd. Analysis and regulation of food intake
US8423130B2 (en) * 2008-05-09 2013-04-16 Metacure Limited Optimization of thresholds for eating detection
CA2733200A1 (en) 2008-08-06 2010-02-11 Novo Nordisk Health Care Ag Conjugated proteins with prolonged in vivo efficacy
WO2010084173A1 (en) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Stable growth hormone compounds
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
WO2011017554A2 (en) * 2009-08-07 2011-02-10 Mannkind Corporation Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
SI2525834T1 (sl) 2010-01-22 2019-10-30 Novo Nordisk Healthcare Ag Rastni hormoni s podaljšano in vivo učinkovitostjo
EP2525833A2 (en) 2010-01-22 2012-11-28 Novo Nordisk Health Care AG Stable growth hormone compounds
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
US20130123460A1 (en) 2010-04-30 2013-05-16 Sanwa Kagaku Kenkyusho Co., Ltd. Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
LT2934567T (lt) 2012-12-21 2018-09-10 Sanofi Eksendino-4 dariniai kaip dvigubi glp1/gip arba trigubi glp1/gip/gliukagono agonistai
ES2841123T3 (es) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Formulación del compuesto de la hormona de crecimiento

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand

Also Published As

Publication number Publication date
EP1496924A4 (en) 2007-05-30
MXPA04009929A (es) 2006-03-10
AU2003220403A1 (en) 2003-10-27
WO2003087139A2 (en) 2003-10-23
EA200401345A1 (ru) 2005-08-25
NZ535684A (en) 2006-03-31
WO2003087139A3 (en) 2004-01-08
ECSP045345A (es) 2006-04-19
KR20040098063A (ko) 2004-11-18
US20050164925A1 (en) 2005-07-28
ZA200408111B (en) 2005-10-07
CN1735423A (zh) 2006-02-15
NO20044815L (no) 2005-01-07
HRP20040939A2 (en) 2004-12-31
JP2005530732A (ja) 2005-10-13
EP1496924A2 (en) 2005-01-19
IL164266A0 (en) 2005-12-18
CA2480858A1 (en) 2003-10-23
PL373658A1 (en) 2005-09-05

Similar Documents

Publication Publication Date Title
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
MXPA03003870A (es) Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes.
WO2003009838A1 (en) Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus
GB0223038D0 (en) Therapeutic compounds
IL194950A0 (en) Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
DE60026704D1 (de) (S,S)-Reboxetine zur Behandlung chronischer Schmerzen
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
GB0225474D0 (en) Therapeutic agents
WO2002096363A3 (en) Method for treating fibrotic diseases or other indications
WO2003049702A3 (en) Vanilloid receptor ligands and their use in treatments
EG24124A (en) Pharmaceutical compositions for the treatment of type-II diabetes mellitus
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
AU2000276362A1 (en) Composition for the treatment of diabetes
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
HK1044483A1 (zh) Il-8受体拮抗剂
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
GB9907571D0 (en) Compounds
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU4937699A (en) Use of succinic acid or salts thereof for the treatment of diabetes mellitus andwound healing
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
NZ504124A (en) Phenyl-alkyl-imidazoles and use in treating inflammatory disease

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A,4A, 5A,6A E 7A ANUIDADES

B08J Incorrect entry in the gazette republished [chapter 8.10 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2051 DE 27/04/2010. TEXTO CORRETO: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.10 DA RPI 2068 DE 24/08/2010.